Patents by Inventor Brian David Judkins

Brian David Judkins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Intermediates for preparing neuraminidase inhibitor conjugates
    Patent number: 7230114
    Abstract: Compounds of formula (I), methods for their preparation and their use in the manufacture of neuraminidase inhibitor conjugates.
    Type: Grant
    Filed: August 30, 2002
    Date of Patent: June 12, 2007
    Assignee: Biota Scientific Management Pty Ltd
    Inventors: Brian David Judkins, Simon John Fawcett MacDonald, Derek Anthony Demaine, Graham George Adam Inglis, Julie Nicole Hamblin
  • Adenosine derivatives and methods of administration
    Patent number: 6677316
    Abstract: A method of treating a patient suffering from or susceptible to ischemic heart disease, peripheral vascular disease or stroke or which subject is suffering pain, a CNS disorder or sleep apnea which comprises administering a therapeutically effective amount of an adenosine derivative which is an agonist at the adenosine A1 receptor and which exhibits little or no agonist activity of the A3 receptor.
    Type: Grant
    Filed: August 13, 2002
    Date of Patent: January 13, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: David Edmund Bays, Richard Peter Charles Cousins, Hazel Joan Dyke, Colin David Eldred, Brian David Judkins, Martin Pass, Andrew Michael Kenneth Pennell
  • Adenosine derivatives
    Publication number: 20030096788
    Abstract: A method of treating a patient suffering from or susceptible to ischemic heart disease, peripheral vascular disease or stroke or which subject is suffering pain, a CNS disorder or sleep apnea which comprises administering a therapeutically effective amount of an adenosine derivative which is an agonist at the adenosine A1 receptor and which exhibits little or no agonist activity of the A3 receptor.
    Type: Application
    Filed: August 13, 2002
    Publication date: May 22, 2003
    Applicant: Glaxo Wellcome Inc.
    Inventors: David Edmund Bays, Richard Peter Charles Cousins, Hazel Joan Dyke, Colin David Eldred, Brian David Judkins, Martin Pass, Andrew Michael Kenneth Pennell
  • Adenosine derivatives
    Patent number: 6492348
    Abstract: A compound of formula (I) which is an agonist at the adenosine Al receptor, wherein Y, Z, and W represent heteroatoms, and salts and solvates thereof, in particular, physiologically acceptable solvates and salts thereof for use in therapy.
    Type: Grant
    Filed: March 6, 2001
    Date of Patent: December 10, 2002
    Assignee: SmithKline Beecham Corporation
    Inventors: David Edmund Bays, Richard Peter Charles Cousins, Hazel Joan Dyke, Colin David Eldred, Brian David Judkins, Martin Pass, Andrew Michael Kenneth Pennell
  • Adenosine analogues and related method of treatment
    Patent number: 6407076
    Abstract: A compound of formula (I) wherein R2 represents C1-3 alkyl, halogen or hydrogen; R3 represents a fluorinated straight or branched alkyl group of 1-6 carbon atoms; and salts and solvates thereof, in particular, physiologically acceptable solvates and salts thereof. These compounds are agonists of the Adenosine A1 receptor.
    Type: Grant
    Filed: June 27, 2000
    Date of Patent: June 18, 2002
    Assignee: SmithKline Beecham Corporation
    Inventors: Philip Charles Box, Brian David Judkins, Andrew Michael Kenneth Pennell